1h Free Analyst Time
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.Speak directly to the analyst to clarify any post sales queries you may have.
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 33 molecules. Out of which approximately 33 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 2, 1, 1, 8, 5 and 1 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Metastatic Colorectal Cancer, Non-Proliferative Diabetic Retinopathy (NPDR), Retinal Vein Occlusion, Retinopathy, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Colorectal Cancer, Corneal Neovascularization, Graves' Ophthalmopathy, Macular Degeneration, Medulloblastoma, Optic Neuropathy, Retinoblastoma, Retinopathy Of Prematurity, Solid Tumor, Unspecified Cancer, Unspecified Ophthalmological Disorders and Uveal Melanoma.
The latest report Placenta Growth Factor - Drugs In Development, 2022, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
- The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
- Alteogen Inc
- Alvotech SA
- Amgen Inc
- Celltrion Inc
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Cinnagen Co
- Formycon AG
- GlycoNex Inc
- Hexal AG
- Huons Global Co Ltd
- i2 Pharmaceuticals Inc
- Johnson & Johnson
- Kidswell Bio Corp
- Luye Pharma Group Ltd
- Mabwell Shanghai Bioscience Co Ltd
- Neuracle Genetics Inc
- Ocular Therapeutix Inc
- Oncosimis Biotech Pvt Ltd
- Oxurion NV
- Panolos Bioscience
- PharmAbcine Inc
- Prestige BioPharma Ltd
- Regeneron Pharmaceuticals Inc
- Rophibio Inc
- Sam Chun Dang Pharm Co Ltd
- Samsung Bioepis Co Ltd
- Shilpa Medicare Ltd
- Synermore Biologics Co Ltd
- Zeen Biotechnology Co Ltd
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
- aflibercept - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept SR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- conbercept - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KH-906 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NG-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PB-101 - Drug Profile
- Product Description
- Mechanism Of Action
- SL-186 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SL-188 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- THR-317 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ziv-aflibercept - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ziv-aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
- Featured News & Press Releases
- Jul 14, 2022: New antibody therapy shows promising results for advanced, treatment-refractory pediatric brain cancer
- Jul 07, 2022: Alvotech initiates patient study for AVT06, a proposed biosimilar for Eylea
- Jun 29, 2022: EYLEA (aflibercept) injection sBLA for Every 16-week dosing regimen in patients with diabetic retinopathy accepted for FDA review
- Apr 25, 2022: Shilpa Medicare receives NoC from RCGM, Dept. of Biotechnology for its Biosimilar Aflibercept
- Feb 22, 2022: Bayer Gets Eylea Biosame approval in Japan as it braces for biosimilar debuts
- Feb 11, 2022: Regeneron presents encouraging phase 2 results for high-dose aflibercept 8 mg in wet age-related macular degeneration at Angiogenesis Meeting
- Nov 10, 2021: Bayer submits Aflibercept for regulatory approval in the EU and Japan for retinopathy of prematurity in premature babies
- Aug 25, 2021: Regeneron’s aflibercept meets primary goal in Phase II wet AMD trial
- Jul 27, 2021: Humana Sues Regeneron Over Price Of Eylea Macular Degeneration Drug
- May 04, 2021: Sandoz to study biosimilar aflibercept in Phase III AMD trial
- Apr 12, 2021: Oncurious reports encouraging data from phase 1 dose escalation study of TB-403 in paediatric subjects with relapsed or refractory medulloblastoma presented at the American Association for Cancer Research 2021 Annual Meeting
- Apr 09, 2021: Kanghong Pharmaceutical stops clinical study of ocular drug Conbercept
- Apr 09, 2021: ONCURIOUS presenting clinical and preclinical data at upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting
- Mar 31, 2021: Regeneron’s Eylea lowers vision-threatening events in diabetes trial
- Mar 28, 2021: Kanghong pharmaceutical: khb-1802 clinical trial suspended in France
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Indications, 2022 (Contd..1)
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alteogen Inc
- Alvotech SA
- Amgen Inc
- Celltrion Inc
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Cinnagen Co
- Formycon AG
- GlycoNex Inc
- Hexal AG
- Huons Global Co Ltd
- i2 Pharmaceuticals Inc
- Johnson & Johnson
- Kidswell Bio Corp
- Luye Pharma Group Ltd
- Mabwell Shanghai Bioscience Co Ltd
- Neuracle Genetics Inc
- Ocular Therapeutix Inc
- Oncosimis Biotech Pvt Ltd
- Oxurion NV
- Panolos Bioscience
- PharmAbcine Inc
- Prestige BioPharma Ltd
- Regeneron Pharmaceuticals Inc
- Rophibio Inc
- Sam Chun Dang Pharm Co Ltd
- Samsung Bioepis Co Ltd
- Shilpa Medicare Ltd
- Synermore Biologics Co Ltd
- Zeen Biotechnology Co Ltd
